| ACES: Azithromycin and Coronary Events Study in patients with stable coronary disease. Discussant. | Crea F. (Rome, IT) | Hot line III - Inflammation in coronary disease. | 30 August 2004 |
| ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Discussant. | Messerli F.H. (New Orleans, US) | Hot line I - Prevention and medical treatment I. | 29 August 2004 |
| Acute coronary syndrome | Serruys P. (Rotterdam, NL) | Drug-eluting stents in challenging subsets. | 31 August 2004 |
| All beta-blockers are alike for the treatment of chronic heart failure: Pro. | Lechat P. (Paris, FR) | Controversies in the diagnosis and treatment of heart failure. | 31 August 2004 |
| Bifurcations | Legrand V. (Liège, BE) | Percutaneous coronary intervention in high-risk subsets | 30 August 2004 |
| Bifurcations | Lefèvre T. (Massy, FR) | Drug-eluting stents in challenging subsets | 31 August 2004 |
| Can we identify good responders? | Stellbrink C. (Aachen, DE) | Resynchronisation therapy in congestive heart failure: questions from the clinician. | 30 August 2004 |
| Can we translate the results of heart failure trials to the grown-up congenital heart disease patients? | Kleber F.X. (Berlin, DE) | Adult congenital heart disease is a cause of chronic heart failure | 29 August 2004 |
| Cardiomyopathies: from phenotype to genotype and back again. | Tajik A.J. (Rochester, US) | ESC lecture on population science. | 30 August 2004 |
| Complications of percutaneous coronary intervention - pathology | Virmani R. (Washington, US) | Complications of percutaneous coronary intervention | 29 August 2004 |
| Conduit arterial stiffness | Dart A. (Melbourne, AU) | Early diagnosis of cardiovascular complications of diabetes by cardiac ultrasound: now ready for clinical application? | 31 August 2004 |
| Contrast-induced nephropathy: can we prevent it? | Ritz E. (Heidelberg, DE) | Complications of percutaneous coronary intervention. | 29 August 2004 |
| Criteria for patient selection. | Di Mario C. (London, GB) | Percutaneous coronary intervention in high-risk subsets. | 30 August 2004 |
| Diabetes and acute coronary syndromes - implications for the cardiologist | Rydén L. (Stockholm, SE) | Caring for patients with type 2 diabetes - a responsibility to be shared between cardiologists and diabetologists | 30 August 2004 |
| Diabetes: the complex link between inflammation, atherosclerosis and thrombosis | De Caterina R. (Chieti, IT) | Diabetes and acute coronary syndromes | 31 August 2004 |
| Distal embolisation: can we prevent it? | Di Mario C. (London, GB) | Complications of percutaneous coronary intervention | 29 August 2004 |
| Distal embolisation: manifestations and consequences | Erbel R. (Essen, DE) | Complications of percutaneous coronary intervention | 29 August 2004 |
| Effective control of paroxismal atrial fibrillation: the big challenge | Blomström-Lundqvist C. (Uppsala, SE) | Everyday management of atrial fibrillation | 29 August 2004 |
| ENCORE II: the long term Effect of Nifedipine on vasomotion and vessel morphology in patients with CORonary artery disease: an intravascular ultrasound-assisted Evaluation. Discussant | Carlier S.G. (New York, US) | Hot line I - Prevention and Medical Treatment I | 29 August 2004 |
| Endothelial dysfunction | Chenzbraun A. (Jerusalem, IL) | Early diagnosis of cardiovascular complications of diabetes by cardiac ultrasound: now ready for clinical application? | 31 August 2004 |
| Genotype and phenotype in hypertrophic cardiomyopathy. | McKenna W.J. (London, GB) | Genetics and arrhythmias | 29 August 2004 |
| How many pills do patients with heart failure actually take? | Erdmann E. (Cologne, DE) | Too many tablets? Is polypharmacy a problem in heart failure? | 31 August 2004 |
| How to assess atrial fibrillation: echocardiography versus magnetic resonance imaging. | Rademakers F.E. (Leuven, BE) | Atrial function in health and disease | 30 August 2004 |
| How to select the candidates for a prophylactic defibrillator among non-ischaemic patients? | Grimm W. (Marburg, DE) | Pitfalls of implantablecardioverter-defibrillator therapy | 30 August 2004 |
| Hypertension and atrial fibrillation: an unavoidable couple | Gonzalez Juanatey J.R. (Santiago de Compostela, ES) | Everyday management of atrial fibrillation | 29 August 2004 |
| ICTUS: Invasive versus Conservative Treatment in Unstable Coronary Syndromes. Discussant | Lindahl B. (Uppsala, Sweden) | Hot line II - Acute coronary syndromes/Medical treatment II | 29 August 2004 |
| Impact of anaemia on cardiac function and prognosis. | Maggioni A.P. (Florence, IT) | Anaemia and beyond in chronic heart failure. | 01 September 2004 |
| Implications of INTERHEART, MONICA, the Seven Countries Study, and other international studies to develop a global approach to cardiovascular disease prevention | Keil U. (Münster, DE) | INTERHEART - A global study of risk factors for acute myocardial infarction in 53 countries | 29 August 2004 |
| In-stent restenosis | Desmet W. (Leuven, BE) | Drug-eluting stents in challenging subsets | 31 August 2004 |
| INTER-HEART: a study of risk factors for first myocardial infarction in 52 countries and over 27,000 subjects. | Després J.P. (Sainte-Foy, CA) | Hot line I - Prevention and medical treatment I | 29 August 2004 |
| JUMBO-TIMI 26: Joint Utilisation of Medications to Block platelets Optimally | Wiviott S.D. (Boston, US) | Hot line II - Acute Coronary Syndromes/Medical Treatment II | 29 August 2004 |
| JUMBO-TIMI 26: Joint Utilisation of Medications to Block platelets Optimally. Discussant | Budaj A. (Warsaw, Poland) | Hot line II - Acute coronay syndromes/Medical treatment II | 29 August 2004 |
| Mechanisms of erythropoietin in chronic heart failure beyond anaemia. | Klein G. (Hannover, DE) | Anaemia and beyond in chronic heart failure. | 01 September 2004 |
| Natriuretic peptides are a substitute to Doppler-echocardiography for the diagnosis of diastolic heart failure: Contra. | Piérard L.A. (Liège, BE) | Controversies in the diagnosis and treatment of heart failure. | 31 August 2004 |
| New medical strategies - do they work? | Gatzoulis M.A. (London, GB) | Pulmonary hypertension in congenital heart disease - new therapeutic aspects. | 01 September 2004 |
| Nicotine replacement therapy and buproprion - benefits and risks. | Fagerström K.O. (Helsingborg, SE) | How to help your patient to quit smoking? | 29 August 2004 |
| Non-antiarrhythmic drugs in the treatment of atrial fibrillation | Hernandez Madrid A. (Madrid, ES) | New antiarrhythmic and antithrombotic drugs for atrial fibrillation | 29 August 2004 |
| Pathophysiological determinants of cardiovascular risk factors in relation to abdominal obesity. | Yudkin J.S. (London, GB) | Abdominal obesity and cardiovascular risk | 01 September 2004 |
| Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids | Leaf A. (Charlestown, US) | Prevention of cardiac arrhythmia by diet | 30 August 2004 |
| PRINCESS: PRevention of Ischaemic eveNts by early treatment of CErivaStatin after acute myocardial infarction | Wright R.S. (Rochester, US) | Hot line III - Inflammation in coronary disease | 30 August 2004 |
| PRINCESS: PRevention of Ischaemic eveNts by early treatment of CErivaStatin after acute myocardial infarction. Discussant | Brady A.J.B. (Glasgow, GB) | Hot line III - Inflammation in coronary disease. | 30 August 2004 |
| PROVE IT-TIMI 22: Pravastatin or Atorvastatin Evaluation and Infection Therapy (Gatifloxacin trial). | Neumann F.J. (Bad Krozingen, DE) | Hot line III - Inflammation in coronary disease. | 30 August 2004 |
| PROVE IT-TIMI 22: Pravastatin or Atorvastatin Evaluation and Infection Therapy (Gatifloxacin trial). | Cannon C.P. (Boston, US) | Hot line III - Inflammation in coronary disease. | 30 August 2004 |
| Results from clinical trials: improved outcome. | Linde C. (Stockholm, SE) | Resynchronisation therapy in congestive heart failure: questions from the clinician. | 30 August 2004 |
| Results from clinical trials: reverse remodelling. | St. John Sutton M. (Philadelphia, US) | Resynchronisation therapy in congestive heart failure: questions from the clinician. | 30 August 2004 |
| RIO-EUROPE: a randomised double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidities. | Van Gaal L. (Edegem-Antwerp, BE) | Hot line I - Prevention and medical treatment I. | 29 August 2004 |
| RIO-EUROPE: a randomised double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidities. Discussant. | Steg P.G. (Paris, FR) | Hot line I - Prevention and medical treatment I. | 29 August 2004 |
| Role of natriuretic peptides. | Kindermann M. (Homburg, DE) | Update on natriuretic peptides in heart failure. | 29 August 2004 |
| Saphenous vein grafts. | Colombo A. (Milan, IT) | Percutaneous coronary intervention in high-risk subsets. | 30 August 2004 |
| Saphenous vein grafts. | Marco J. (Toulouse, France) | Drug-eluting stents in challenging subsets. | 31 August 2004 |
| SENIORS: Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with heart failure. | Coats A.J.S. (Sydney, AU) | Hot line II - Acute Coronary Syndromes/Medical treatment II | 29 August 2004 |
| Sympathetic activity and arrhythmias in long QT: a missing link? | Wilde A.A.M. (Amsterdam, NL) | Understanding congenital ventricular arrhythmias: basic science meets the clinician | 30 August 2004 |
| Techniques and strategies. | Fajadet J. (Toulouse, France) | Percutaneous coronary intervention in high-risk subsets. | 30 August 2004 |
| Unprotected left main | Wilensky R.L. (Philadelphia, US) | Percutaneous coronary intervention in high-risk patients | 30 August 2004 |
| Unraveling the genetics of heart attack | Topol E.J. (Cleveland, US) | ESC lecture on clinical cardiology - The Grüntzig lecture | 31 August 2004 |